Cognitive impairments in first-episode psychosis patients with attenuated niacin response

MingLiang Ju, Bin Long, YanYan Wei, XiaoChen Tang, Lihua Xu, RanPiao Gan, HuiRu Cui, Yingying Tang, Zhenghui Yi, HaiChun Liu, Zixuan Wang, Tao Chen, Jin Gao, Qiang Hu, Lingyun Zeng, Chunbo Li, Jijun Wang, HuanZhong Liu, Tianhong ZhangSchizophrenia 2025 · DOI

TL;DR

This study identifies a specific subtype of first-episode psychosis (FEP) patients, characterized by an "attenuated niacin response" (ANR), who exhibit more severe negative symptoms and significant cognitive impairments, particularly in processing speed and visuospatial memory. This finding suggests that ANR may represent a distinct biological subtype of psychosis, paving the way for more targeted diagnostic and therapeutic approaches.

What Problem Does This Paper Address?

Psychosis, a complex brain disorder, is thought to encompass various biological subtypes that influence treatment response. Identifying these subtypes is crucial for developing effective interventions. One potential endophenotype, or observable trait linked to a genetic predisposition, is the "attenuated niacin response" (ANR), which is characterized by a blunted skin flush after topical niacin application. Previous research has linked ANR to more severe negative symptoms and functional impairments in psychosis. However, there's a significant knowledge gap regarding the specific cognitive deficits associated with the ANR subtype, especially in drug-naive first-episode psychosis (FEP) patients, who represent an early stage of the illness before long-term medication effects can confound findings. This paper aims to fill this gap by comprehensively assessing the cognitive profiles of FEP patients with and without ANR.

Methods

This observational study employed a cross-sectional design involving 54 drug-naive FEP patients and 52 matched healthy controls (HC).

  • Clinical Assessment: Psychopathology was evaluated using the Positive and Negative Syndrome Scale (PANSS), which measures positive, negative, and general psychopathology symptoms.
  • Cognitive Assessment: Neurocognitive performance was assessed using the Chinese version of the MATRICS Consensus Cognitive Battery (MCCB), a standardized battery for evaluating cognitive function in individuals with psychosis. This included tests for processing speed, attention, memory, and executive function.
  • Niacin Response Measurement: The ANR was identified using a standardized topical niacin skin test with aqueous methylnicotinate patches. Skin flush responses were measured and quantified. Participants were classified as having an ANR (total score < 20 and a specific score at 15 minutes) or a normal niacin response (NNR).

Statistical analyses included t-tests and chi-square tests to compare groups, correlation analyses to examine relationships between variables, and Z-score transformations for visualizing group differences in a radar chart.

Datasets

Not discussed in the paper. The study collected data from participants recruited from the Shanghai Mental Health Center.

Key Insights and Ideas

  • ANR as a Distinct Subtype: The study strongly suggests that the ANR subtype is not just a marker of general psychosis but represents a distinct clinical and cognitive profile within FEP.
  • Niacin Response and Symptoms: A significant positive correlation was found between overall symptom severity and niacin response, and more specifically, between negative symptoms and niacin response. This reinforces the idea that niacin response is linked to the core symptomatology of psychosis.
  • Cognitive Vulnerability: The ANR subtype is associated with more pronounced cognitive deficits, particularly in areas crucial for daily functioning, suggesting a potential biological basis for these impairments.
  • Implications for Treatment: Identifying ANR early could allow for more tailored interventions, potentially improving outcomes for this specific patient group.

Key Results

  • Prevalence of ANR: Approximately 25.9% of FEP patients exhibited an attenuated niacin response, which was significantly higher than the 7.7% observed in healthy controls.
  • Clinical Differences: ANR patients showed significantly more severe negative symptoms and higher total PANSS scores compared to NNR patients.
  • Cognitive Deficits: ANR patients performed significantly worse on the Trail Making Test A (assessing processing speed, attention, and executive function) and the Brief Visuospatial Memory Test-Revised (BVMT-R) compared to NNR patients.
  • Correlations: A significant positive correlation was observed between overall cognitive scores and niacin response, and specifically between Trail Making A and BACS symbol coding scores and niacin response. Negative symptoms were significantly correlated with poorer performance on the Trail Making A test.

Limitations and Future Work

  • Sample Size and Generalizability: The authors acknowledge that the sample size, while sufficient for preliminary findings, may limit the generalizability of the results to broader populations. A larger and more diverse cohort is recommended.
  • Cross-Sectional Design: The study's cross-sectional nature prevents drawing causal inferences about the relationship between ANR and cognitive function. Longitudinal studies are needed to track changes over time.
  • Broader Cognitive Assessment: While the MCCB is comprehensive, the authors suggest that future research should consider including social cognition assessments, which were not part of this study.
  • Confounding Variables: The observational design means that not all potential confounding variables (e.g., environmental factors, comorbid conditions) could be controlled.
  • Future Directions: The paper highlights the potential for developing novel treatments, including nutritional interventions (e.g., PUFAs, sulforaphane) and targeted neuromodulation (e.g., TMS), for the ANR subtype. Further research into the underlying mechanisms of ANR and its link to neuroinflammation and oxidative stress is also encouraged.

Summary updated

Abstract

This study demonstrates that the ANR subtype in first-episode psychosis is linked to more severe negative symptoms and cognitive impairments. Targeted assessments and interventions for patients with ANR may improve treatment outcomes and enhance understanding of cognitive dysfunction in psychotic disorders.
BibTeX
@inproceedings{ju2025cognitive,
  author = {MingLiang Ju and Bin Long and YanYan Wei and XiaoChen Tang and Lihua Xu and RanPiao Gan and HuiRu Cui and Yingying Tang and Zhenghui Yi and HaiChun Liu and Zixuan Wang and Tao Chen and Jin Gao and Qiang Hu and Lingyun Zeng and Chunbo Li and Jijun Wang and HuanZhong Liu and Tianhong Zhang and HuanZhong Liu and TianHong Zhang},
  title = {{Cognitive impairments in first-episode psychosis patients with attenuated niacin response}},
  booktitle = {Schizophrenia},
  year = {2025},
  doi = {10.1016/j.scog.2025.100346},
}
Figure